ClinVar Miner

Submissions for variant NM_003640.5(ELP1):c.312T>A (p.Cys104Ter)

gnomAD frequency: 0.00002  dbSNP: rs1291760879
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 4
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Eurofins Ntd Llc (ga) RCV000596363 SCV000707658 uncertain significance not provided 2017-04-11 criteria provided, single submitter clinical testing
Illumina Laboratory Services, Illumina RCV000778872 SCV000915269 uncertain significance Familial dysautonomia 2017-10-09 criteria provided, single submitter clinical testing Variants in the IKBKAP gene have been associated with familial dysautonomia. The IKBKAP c.312T>A (p.Cys104Ter) variant is a stop-gained variant predicted to result in premature termination of the protein. The variant was observed by ICSL as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018) and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score for this variant, it could not be ruled out of causing disease and therefore its association with disease required further investigation. A literature search was performed for the gene, cDNA change, and amino acid change. No publications were found based on this search. Due to the potential impact of stop-gained variants and the lack of clarifying evidence, this variant is classified as a variant of unknown significance but suspicious for pathogenicity for familial dysautonomia.
Invitae RCV000596363 SCV001412868 pathogenic not provided 2023-10-22 criteria provided, single submitter clinical testing This sequence change creates a premature translational stop signal (p.Cys104*) in the ELP1 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in ELP1 are known to be pathogenic (PMID: 18303054, 24173031). This variant is present in population databases (no rsID available, gnomAD 0.002%). This variant has not been reported in the literature in individuals affected with ELP1-related conditions. ClinVar contains an entry for this variant (Variation ID: 501334). For these reasons, this variant has been classified as Pathogenic.
Preventiongenetics, part of Exact Sciences RCV003403403 SCV004105361 likely pathogenic ELP1-related condition 2023-06-27 criteria provided, single submitter clinical testing The ELP1 c.312T>A variant is predicted to result in premature protein termination (p.Cys104*). This variant has been reported in an individual with medulloblastoma (Extended Data Table 2, Waszak et al. 2020. PubMed ID: 32296180). This variant is reported in 0.0023% of alleles in individuals of European (Non-Finnish) descent in gnomAD (http://gnomad.broadinstitute.org/variant/9-111689725-A-T). Nonsense variants in ELP1 are expected to be pathogenic. This variant is interpreted as likely pathogenic.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.